Dediabetes Logo
Evidence Hub
Learn what works
Latest Research
Newest studies
What Changed
Weekly intelligence
Settings
Login / Sign up
Research Summary
Analyzed using Evidence Intelligence™

Tirzepatide shows greater HbA1c and weight reduction than Semaglutide

Powered by the Dediabetes Evidence Intelligence™ framework

Key finding

In Hispanic or Latino patients, the LSM change from baseline in HbA1c at 40 weeks was -2.11% with Tirzepatide 5 mg (p<0.001).

This study compared the effects of Tirzepatide and Semaglutide on HbA1c and body weight in Hispanic or Latino patients with Type 2 Diabetes, finding significant reductions with Tirzepatide.

Evidence strength

Moderate confidence

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Some Concerns bias
Last updated July 4, 2026

Quick read

Study at a glance

The essential study design details in one scan.

Population

Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes

Intervention

Tirzepatide 5 mg, Semaglutide 1 mg

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Primary outcome

HbA1c reduction with Tirzepatide 5 mg

Comparator

Semaglutide 1 mg

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

This study compared the effects of Tirzepatide and Semaglutide on HbA1c and body weight in Hispanic or Latino patients with Type 2 Diabetes, finding significant reductions with Tirzepatide.

Clinical relevance

These findings are clinically significant as they suggest that Tirzepatide may offer superior glycemic control and weight management for Hispanic or Latino patients with Type 2 Diabetes. This could lead to improved health outcomes and quality of life for patients in this demographic, who may respond differently to diabetes treatments.

Keep in mind

The study focused only on Hispanic or Latino patients, limiting generalizability. Results may not apply to patients with other ethnic backgrounds. Long-term effects beyond 40 weeks were not assessed.

Published in

Journal Reference

Publication details and source links for this paper.

Brian DB, Katelyn B, Raleigh EM, Hui W, Juan PF. Tirzepatide versus Semaglutide in Hispanic or Latino Patients with Type 2 Diabetes: A Subgroup Analysis of SURPASS-2. Journal of the Endocrine Society. 2022;6(Suppl 1):A355-A356. doi:10.1210/jendso/bvac150.738

View DOIView on PMC

Save this study and add notes to your research library.

Main Effects

Tirzepatide 5 mg reduced HbA1c by -2.11% (p<0.001).

Tirzepatide 10 mg reduced HbA1c by -2.46% (p<0.001).

Tirzepatide 15 mg reduced HbA1c by -2.47% (p<0.001).

Semaglutide reduced HbA1c by -1.93% (p<0.001).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Semaglutide, Tirzepatide and Body weight, HbA1c, Weight change.

This study contributes evidence to

Intervention

Semaglutide

Outcome

Body weight

Evidence topic

Weight Loss

Primary intervention

Semaglutide

Primary outcomes

  • Body weight
  • HbA1c
  • Weight change

Evidence topics

Weight LossHbA1c ReductionGLP-1 Receptor Agonists

Primary intervention

Semaglutide

Primary outcomes

Body weightHbA1cWeight change

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

5
Evidence pairs
5
Relationships
3
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 68

3

Related topics

5

Evidence pairs

291

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 5 evidence relationships
  • Includes primary outcome data
  • Linked to 3 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Core evidence

Study findings

The primary outcomes reported in this study.

Body weight

Semaglutide → Body weight

Semaglutide → Body weight

Evidence Intelligence™
ImpactScore™
80
Positive
EvidenceScore™
87
Strong
ConsistencyScore™
89
consistent
Supporting studies: Based on 10 studies
Unlock full evidence details

HbA1c

Semaglutide → HbA1c

Semaglutide → HbA1c

Evidence Intelligence™
ImpactScore™
87
Very Positive
EvidenceScore™
87
Strong
ConsistencyScore™
82
consistent
Supporting studies: Based on 11 studies
Unlock full evidence details

Body weight

Tirzepatide → Body weight

Tirzepatide → Body weight

Evidence Intelligence™
ImpactScore™
100
Very Positive
EvidenceScore™
83
Strong
ConsistencyScore™
100
consistent
Supporting studies: Based on 7 studies
Unlock full evidence details

HbA1c

Tirzepatide → HbA1c

Tirzepatide → HbA1c

Evidence Intelligence™
ImpactScore™
100
Very Positive
EvidenceScore™
85
Strong
ConsistencyScore™
100
consistent
Supporting studies: Based on 8 studies
Unlock full evidence details

Weight change

Tirzepatide → Weight change

Tirzepatide → Weight change

Evidence Intelligence™
ImpactScore™
100
Very Positive
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Unlock full evidence details

Unlock full evidence analysis

Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.

evidence suggest

Evidence Suggest

  • Tirzepatide 10 mg led to a body weight reduction of -9.7 kg (p<0.001).
  • Tirzepatide 15 mg resulted in a body weight reduction of -10.5 kg (p<0.001).
  • Semaglutide resulted in a body weight reduction of -5.6 kg (p<0.001).
who this applies

Who this applies to

  • Hispanic or Latino adults with Type 2 Diabetes.
  • Patients seeking effective glycemic control and weight management.
keep in mind

Keep in Mind

  • The study's findings are specific to Hispanic or Latino patients.
  • Further research is needed to confirm long-term effects.
  • Individual responses to treatment may vary.
between the lines

Between the Lines

  • The study focused only on Hispanic or Latino patients, limiting generalizability.
  • Results may not apply to patients with other ethnic backgrounds.
  • Long-term effects beyond 40 weeks were not assessed.

Unlock Full Analysis

Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.

Already have an account?

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Powered by the Dediabetes Evidence Intelligence™ framework

This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.

Related evidence relationships

Explore in Evidence Archive

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does GLP-1 Receptor Agonists affect body weight?

Strong Evidence

GLP-1 Receptor Agonists may improve Body Weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Body weight

    EvidenceScore™ Strong | EvidenceScore™ 86.5 | moderate positive | ConsistencyScore™ Consistent | 1 study

  2. 2

    Weight change

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 23 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
23 supporting studiesUpdated: Jul 2026
View Full Evidence

Does GLP-1 Receptor Agonists improve HbA1c?

Strong Evidence

GLP-1 Receptor Agonists appears to improve HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    HbA1c

    EvidenceScore™ Strong | EvidenceScore™ 86.5 | strong positive | ConsistencyScore™ Consistent | 1 study

Why this answer: This answer is based on 24 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
24 supporting studiesUpdated: Jul 2026
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, archive views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Weight Loss Evidence HubHbA1c Reduction Evidence HubGLP-1 Receptor Agonists Evidence Hub

Explore in archive

Open broader archive views for this relationship.

All studies on Semaglutide and HbA1cAll studies on Semaglutide and Body weightAll studies on Tirzepatide and HbA1cAll studies on Tirzepatide and Body weight

Related research

Read related research summaries.

Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesSemaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesTirzepatide improves glycemic control in early-onset type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetes

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.